GFRA2

GFRA2 is a GPI-anchored co-receptor that preferentially binds neurturin (NRTN) and, with lower affinity, GDNF, recruiting the RET receptor tyrosine kinase to form a signaling complex that activates downstream kinase cascades (PMID:9182803). The crystal structure of the NRTN–GFRα2 complex reveals that domain 1 of GFRα2 does not contact NRTN but presents a conserved surface for RET and/or NCAM interaction, and heparan sulfate participates in signaling-complex assembly through binding sites on both NRTN and GFRα2 (PMID:29414779). In pancreatic cancer cells, NRTN-induced GFRA2–RET signaling phosphorylates hexokinase 2 (HK2) at Ser122, augmenting glycolysis and tumor growth (PMID:39988080). GFRA2 also functions in a RET-independent pathway in cardiac progenitor cells, where it is required for cardiomyocyte differentiation (PMID:27396331).

1. 1997 High

   Establishing the identity of GFRA2 as a GPI-linked co-receptor that pairs with RET to transduce neurturin signaling with ~30-fold preference over GDNF answered the fundamental question of how NTN signals at the cell surface and defined the ligand–co-receptor–kinase paradigm for this family.

   Evidence Reconstitution in fibroblasts co-expressing TrnR2/GFRA2 and RET with quantitative ligand sensitivity measurements

   PMID:9182803

   Open questions at the time

   • No structural basis for ligand selectivity or RET recruitment
   • Whether GFRA2 can signal independently of RET was untested
   • Downstream signaling targets beyond RET autophosphorylation were uncharacterized
2. 2016 Medium

   Discovery that GFRA2 marks cardiac progenitor cells and drives cardiomyocyte differentiation through a RET-independent pathway expanded the receptor's functional repertoire beyond the nervous system and demonstrated a non-canonical signaling mode.

   Evidence FACS isolation of GFRA2+ cardiac progenitors from mouse/human pluripotent stem cells; Gfra2 knockout mouse with cardiomyocyte differentiation defects

   PMID:27396331

   Open questions at the time

   • RET-independence inferred genetically but not biochemically reconstituted
   • Downstream effectors of the RET-independent pathway remain unidentified
   • Ligand for GFRA2 in cardiac progenitor context not definitively established
3. 2018 High

   The crystal structure of NRTN–GFRα2 resolved how the co-receptor engages its ligand and revealed that domain 1 is free to interact with RET or NCAM, while identifying heparan sulfate–binding sites on both NRTN and GFRα2 that participate in complex assembly.

   Evidence X-ray crystallography of NRTN alone and NRTN–GFRα2 complex; mutagenesis of heparan sulfate–binding residues; cell-based functional assays

   PMID:29414779

   Open questions at the time

   • No structure of the ternary NRTN–GFRα2–RET complex
   • Functional significance of the putative NCAM interaction surface not validated
   • Heparan sulfate contribution quantified only through NRTN mutants, not GFRα2 mutants
4. 2025 Medium

   Identification of HK2 Ser122 as a direct phosphorylation target downstream of the NRTN–GFRA2–RET complex linked co-receptor signaling to metabolic reprogramming (aerobic glycolysis) in pancreatic cancer, providing the first specific kinase substrate for this pathway in a cancer context.

   Evidence Phosphorylation site mapping of HK2; metabolomics; in vivo xenograft models with neurturin blockade and RET inhibitor combination

   PMID:39988080

   Open questions at the time

   • Single-lab finding; independent replication of HK2 Ser122 phosphorylation by GFRA2-RET pending
   • Whether RET directly phosphorylates HK2 or acts through an intermediate kinase is unresolved
   • Generalizability of this metabolic mechanism to other GFRA2-expressing cancers untested

• A ternary NRTN–GFRα2–RET structure, the identity of the downstream effectors in RET-independent cardiac signaling, and the breadth of GFRA2-driven metabolic rewiring across tissues remain open questions.
• No ternary complex structure resolved
• RET-independent signaling pathway effectors unidentified
• Scope of HK2/glycolysis regulation by GFRA2-RET beyond pancreatic cancer unknown